Brenda L Banwell

List of Publications by Year
in descending order

154 papers	14,508 citations	81839 39 h-index	20943 115 g-index
161 all docs	161 docs citations	161 times ranked	11422 citing authors

#	Article	IF	Citations
1	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, The, 2018, 17, 162-173.	4.9	4,605
2	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 2015, 85, 177-189.	1.5	3,275
3	MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurology, The, 2016, 15, 292-303.	4.9	679
4	Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurology, The, 2007, 6, 887-902.	4.9	341
5	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain, 2019, 142, 1858-1875.	3.7	303
6	2021 MAGNIMSâ€“CMSCâ€“NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurology, The, 2021, 20, 653-670.	4.9	302
7	Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurology, The, 2007, 6, 773-781.	4.9	292
8	Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology, 2014, 83, 142-150.	1.5	275
9	Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurology, The, 2011, 10, 436-445.	4.9	267
10	Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurology, The, 2021, 20, 762-772.	4.9	261
11	Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. New England Journal of Medicine, 2018, 379, 1017-1027.	13.9	237
12	Serial Antiâ€“Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes. JAMA Neurology, 2020, 77, 82.	4.5	213
13	The cognitive burden of multiple sclerosis in children. Neurology, 2005, 64, 891-894.	1.5	165
14	Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. Lancet Neurology, The, 2014, 13, 936-948.	4.9	124
15	Treatment Approaches for MOG-Ab-Associated Demyelination in Children. Current Treatment Options in Neurology, 2019, 21, 2.	0.7	109
16	Analyzing 2,589 child neurology telehealth encounters necessitated by the COVID-19 pandemic. Neurology, 2020, 95, e1257-e1266.	1.5	108
17	Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth. Neurology, 2014, 83, 2140-2146.	1.5	107
18	MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. The Lancet Child and Adolescent Health, 2018, 2, 191-204.	2.7	86

#	Article	IF	Citations
19	Neurotoxicity after CTL019 in a pediatric and young adult cohort. Annals of Neurology, 2018, 84, 537-546.	2.8	82
20	Pilot study of a ketogenic diet in relapsing-remitting MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e565.	3.1	82
21	Abnormal Tâ€cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes. Annals of Neurology, 2008, 63, 98-111.	2.8	77
22	Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis. Brain, 2019, 142, 617-632.	3.7	72
23	Quantitative Determination of Regional Lesion Volume and Distribution in Children and Adults with Relapsing-Remitting Multiple Sclerosis. PLoS ONE, 2014, 9, e85741.	1.1	64
24	Lower physical activity is associated with higher disease burden in pediatric multiple sclerosis. Neurology, 2015, 85, 1663-1669.	1.5	62
25	Clinical trials of disease-modifying agents in pediatric MS. Neurology, 2019, 92, e2538-e2549.	1.5	62
26	Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care. Lancet Neurology, The, 2021, 20, 136-149.	4.9	60
27	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 2015, 72, 815.	4.5	59
28	Consensus definitions for pediatric MS and other demyelinating disorders in childhood. Neurology, 2016, 87, S8-S11.	1.5	59
29	Epitope spreading as an early pathogenic event in pediatric multiple sclerosis. Neurology, 2014, 83, 2219-2226.	1.5	58
30	Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease. Annals of the Rheumatic Diseases, 2015, 74, 204-210.	0.5	56
31	Delayed Primary HHV-7 Infection and Neurologic Disease. Pediatrics, 2014, 133, e1541-e1547.	1.0	53
32	White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders. Brain, 2017, 140, 1300-1315.	3.7	52
33	Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination. Multiple Sclerosis Journal, 2016, 22, 385-388.	1.4	50
34	Puberty in females enhances the risk of an outcome of multiple sclerosis in children and the development of central nervous system autoimmunity in mice. Multiple Sclerosis Journal, 2015, 21, 735-748.	1.4	47
35	Outcomes After Early Administration of Plasma Exchange in Pediatric Central Nervous System Inflammatory Demyelination. Journal of Child Neurology, 2015, 30, 874-880.	0.7	46
36	Impact of an <scp>ICU EEG</scp> monitoring pathway on timeliness of therapeutic intervention and electrographic seizure termination. Epilepsia, 2016, 57, 786-795.	2.6	46

#	Article	IF	Citations
37	Therapies for multiple sclerosis: considerations in the pediatric patient. Nature Reviews Neurology, 2011, 7, 109-122.	4.9	43
38	Monophasic demyelination reduces brain growth in children. Neurology, 2017, 88, 1744-1750.	1.5	43
39	MRI in the evaluation of pediatric multiple sclerosis. Neurology, 2016, 87, S88-96.	1.5	42
40	Rituximab as a first-line preventive treatment in pediatric NMOSDs. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e46.	3.1	41
41	Neuroimmune disorders of the central nervous system in children in the molecular era. Nature Reviews Neurology, 2018, 14, 433-445.	4.9	41
42	Recovery From Central Nervous System Acute Demyelination in Children. Pediatrics, 2015, 136, e115-e123.	1.0	40
43	Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4-diaminopyridine. Neuromuscular Disorders, 2004, 14, 202-207.	0.3	39
44	Contribution of the cerebellum to cognitive performance in children and adolescents with multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 599-607.	1.4	38
45	Functionalâ€“structural correlations in the afferent visual pathway in pediatric demyelination. Neurology, 2014, 83, 2147-2152.	1.5	37
46	Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 1001-1011.	4.9	36
47	Age of Onset as a Moderator of Cognitive Decline in Pediatric-Onset Multiple Sclerosis. Journal of the International Neuropsychological Society, 2014, 20, 796-804.	1.2	34
48	Common and variable clinical, histological, and imaging findings of recessive RYR1-related centronuclear myopathy patients. Neuromuscular Disorders, 2017, 27, 975-985.	0.3	34
49	The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes. Annals of Clinical and Translational Neurology, 2021, 8, 2252-2269.	1.7	34
50	Physical Activity and Its Correlates in Youth with Multiple Sclerosis. Journal of Pediatrics, 2016, 179, 197-203.e2.	0.9	33
51	Silent New Brain MRI Lesions in Children with MOGâ€Antibody Associated Disease. Annals of Neurology, 2021, 89, 408-413.	2.8	33
52	Optical coherence tomography and visual evoked potentials in pediatric MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e356.	3.1	32
53	The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk. Multiple Sclerosis Journal, 2019, 25, 515-522.	1.4	32
54	Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 175-185.	1.4	30

#	Article	IF	Citations
55	Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective. JAMA Neurology, 2021, 78, 351.	4.5	30
56	Pediatric Multiple Sclerosis: an Update. Current Neurology and Neuroscience Reports, 2018, 18, 76.	2.0	29
57	BTK inhibition limits B-cellâ€"T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy. Acta Neuropathologica, 2022, 143, 505-521.	3.9	29
58	Pediatric multiple sclerosis. Current Neurology and Neuroscience Reports, 2004, 4, 245-252.	2.0	28
59	Alterations in Functional and Structural Connectivity in Pediatric-Onset Multiple Sclerosis. PLoS ONE, 2016, 11, e0145906.	1.1	28
60	Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes. JAMA Network Open, 2021, 4, e2128871.	2.8	27
61	Magnetization transfer ratio recovery in new lesions decreases during adolescence in pediatric-onset multiple sclerosis patients. NeuroImage: Clinical, 2014, 6, 237-242.	1.4	26
62	Incidence and prevalence of MS in children. Neurology, 2018, 91, e1579-e1590.	1.5	26
63	Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 483-492.	0.9	26
64	Endocrine and Growth Abnormalities in 4H Leukodystrophy Caused by Variants in POLR3A, POLR3B, and POLR1C. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e660-e674.	1.8	26
65	Elevated Cerebrospinal Fluid Opening Pressure in a Pediatric Demyelinating Disease Cohort. Pediatric Neurology, 2015, 52, 446-449.	1.0	23
66	Hospital admission rates for pediatric multiple sclerosis in the United States using the Pediatric Health Information System (PHIS). Multiple Sclerosis and Related Disorders, 2016, 9, 5-10.	0.9	23
67	Consistent control of disease activity with fingolimod versus IFN Î²-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 91, jnnp-2019-321124.	0.9	22
68	Impaired growth of the cerebellum in pediatric-onset acquired CNS demyelinating disease. Multiple Sclerosis Journal, 2016, 22, 1266-1278.	1.4	21
69	Brain activation patterns and cognitive processing speed in patients with pediatric-onset multiple sclerosis. Journal of Clinical and Experimental Neuropsychology, 2016, 38, 393-403.	0.8	21
70	Pediatric-onset multiple sclerosis is associated with reduced parental healthâ€"related quality of life and family functioning. Multiple Sclerosis Journal, 2019, 25, 1661-1672.	1.4	21
71	Altered resting-state functional connectivity in cognitively preserved pediatric-onset MS patients and relationship to structural damage and cognitive performance. Multiple Sclerosis Journal, 2016, 22, 792-800.	1.4	20
72	International Pediatric MS Study Group Global Members Symposium report. Neurology, 2016, 87, S110-6.	1.5	19

#	Article	IF	Citations
73	Subcutaneous interferon Î²-1a in pediatric patients with multiple sclerosis: Regional differences in clinical features, disease management, and treatment outcomes in an international retrospective study. Journal of the Neurological Sciences, 2016, 363, 33-38.	0.3	19
74	Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations. Multiple Sclerosis Journal, 2021, 27, 1814-1822.	1.4	19
75	Assessing seizure burden in pediatric epilepsy using an electronic medical recordâ€“based tool through a common data element approach. Epilepsia, 2021, 62, 1617-1628.	2.6	19
76	Multiple sclerosis in children. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 427-441.	1.0	18
77	Deep learning segmentation of orbital fat to calibrate conventional MRI for longitudinal studies. NeuroImage, 2020, 208, 116442.	2.1	17
78	Quantitative Measurement of tissue damage and recovery within new T2w lesions in pediatric- and adult-onset multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 718-725.	1.4	16
79	Impact of an electronic monitoring device and behavioral feedback on adherence to multiple sclerosis therapies in youth: results of a randomized trial. Quality of Life Research, 2017, 26, 2333-2349.	1.5	16
80	What does first-line therapy mean for paediatric multiple sclerosis in the current era?. Multiple Sclerosis Journal, 2021, 27, 1970-1976.	1.4	16
81	Evaluation of fall Sun Exposure Score in predicting vitamin D status in young Canadian adults, and the influence of ancestry. Journal of Photochemistry and Photobiology B: Biology, 2015, 145, 25-29.	1.7	15
82	7T MRI Visualization of Cortical Lesions in Adolescents and Young Adults with Pediatricâ€Onset Multiple Sclerosis. Journal of Neuroimaging, 2017, 27, 447-452.	1.0	15
83	High rates of health care utilization in pediatric multiple sclerosis: A Canadian population-based study. PLoS ONE, 2019, 14, e0218215.	1.1	15
84	Acceptability of Standardized EEG Reporting in an Electronic Health Record. Journal of Clinical Neurophysiology, 2020, 37, 455-461.	0.9	15
85	Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome. Neurology, 2022, 98, .	1.5	15
86	Guilty by association: Epsteinâ€“Barr virus in multiple sclerosis. Nature Medicine, 2022, 28, 904-906.	15.2	15
87	MLIP causes recessive myopathy with rhabdomyolysis, myalgia and baseline elevatedÂ serum creatine kinase. Brain, 2021, 144, 2722-2731.	3.7	14
88	An update on multiple sclerosis in children: diagnosis, therapies, and prospects for the future. Expert Review of Clinical Immunology, 2017, 13, 975-989.	1.3	12
89	Involvement of the Amygdala in Memory and Psychosocial Functioning in Pediatric-Onset Multiple Sclerosis. Developmental Neuropsychology, 2018, 43, 524-534.	1.0	12
90	Ethical use of off-label disease-modifying therapies for multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1403-1410.	1.4	12

#	Article	IF	Citations
91	Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria. Multiple Sclerosis Journal, 2022, 28, 1697-1709.	1.4	12
92	Normalization of White Matter Intensity on T1â€Weighted Images of Patients with Acquired Central Nervous System Demyelination. Journal of Neuroimaging, 2015, 25, 184-190.	1.0	11
93	Binocular low-contrast letter acuity and the symbol digit modalities test improve the ability of the Multiple Sclerosis Functional Composite to predict disease in pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 10, 73-78.	0.9	11
94	Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI. Multiple Sclerosis Journal, 2019, 25, 980-986.	1.4	11
95	Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS. Acta Neuropathologica Communications, 2020, 8, 207.	2.4	11
96	Fast automatic segmentation of thalamic nuclei from MP2RAGE acquisition at 7 Tesla. Magnetic Resonance in Medicine, 2021, 85, 2781-2790.	1.9	11
97	Increased mental health care use by mothers of children with multiple sclerosis. Neurology, 2020, 94, e1040-e1050.	1.5	10
98	Degos disease mimicking primary vasculitis of the CNS. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e206.	3.1	9
99	Adverse events associated with a large dose of intravenous lipid emulsion for suspected local anesthetic toxicity. Clinical Toxicology, 2017, 55, 603-607.	0.8	9
100	Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1948-1959.	1.4	9
101	Attitudes, perceptions, and use of marijuana in youth with multiple sclerosis. Journal of Neurology, 2018, 265, 417-423.	1.8	8
102	Hemicraniectomy and externalized ventricular drain placement in a pediatric patient with myelin oligodendrocyte glycoprotein-associated tumefactive demyelinating disease. Child's Nervous System, 2022, 38, 185-189.	0.6	8
103	The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome. Multiple Sclerosis and Related Disorders, 2022, 63, 103829.	0.9	8
104	Cognitive and Behavioral Functioning in Childhood Acquired Demyelinating Syndromes. Journal of the International Neuropsychological Society, 2016, 22, 1050-1060.	1.2	7
105	Slowâ€channel myasthenia due to novel mutation in M2 domain of AChR delta subunit. Annals of Clinical and Translational Neurology, 2019, 6, 2066-2078.	1.7	7
106	A feasibility study of working memory training for individuals with paediatric-onset multiple sclerosis. Neuropsychological Rehabilitation, 2019, 29, 1177-1192.	1.0	7
107	Factors associated with health care utilization in pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 38, 101511.	0.9	7
108	Health-care disparities for people with multiple sclerosis. Lancet Neurology, The, 2020, 19, 207-208.	4.9	7

#	Article	IF	Citations
109	Treatment of multiple sclerosis in children and its challenges. Presse Medicale, 2015, 44, e153-e158.	0.8	6
110	Effects of Optic Neuritis, T2 Lesions, and Microstructural Diffusion Integrity in the Visual Pathway on Cortical Thickness in Pediatricâ€Onset Multiple Sclerosis. Journal of Neuroimaging, 2019, 29, 760-770.	1.0	6
111	Structural correlates of atypical visual and motor cortical oscillations in pediatricâ€onset multiple sclerosis. Human Brain Mapping, 2020, 41, 4299-4313.	1.9	6
112	Understanding risk of relapse and risk of disability after childhood transverse myelitis. Neurology, 2015, 84, 332-334.	1.5	5
113	World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application. Multiple Sclerosis Journal, 2020, 26, 153-158.	1.4	5
114	Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study. Multiple Sclerosis Journal, 2021, 27, 922-932.	1.4	5
115	Examining cognitive speed and accuracy dysfunction in youth and young adults with pediatric-onset multiple sclerosis using a computerized neurocognitive battery.. Neuropsychology, 2021, 35, 388-398.	1.0	5
116	Current international trends in the treatment of multiple sclerosis in childrenâ€"Impact of the COVID-19 pandemic. Multiple Sclerosis and Related Disorders, 2021, 56, 103277.	0.9	5
117	Cognitive function in pediatric-onset relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Multiple Sclerosis and Related Disorders, 2022, 59, 103689.	0.9	5
118	Pediatric multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 112, 1263-1274.	1.0	4
119	Increased relapse rate during pregnancy and postpartum in neuromyelitis optica. Neurology, 2017, 89, 2220-2221.	1.5	4
120	Maturational Trajectory of Processing Speed Performance in Pediatric Multiple Sclerosis. Developmental Neuropsychology, 2017, 42, 299-308.	1.0	4
121	Physical activity and dentate gyrus volume in pediatric acquired demyelinating syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e499.	3.1	4
122	Early neuroaxonal injury is seen in the acute phase of pediatric optic neuritis. Multiple Sclerosis and Related Disorders, 2019, 36, 101387.	0.9	4
123	Defective complex III mitochondrial respiratory chain due to a novel variant in CYC1 gene masquerades acute demyelinating syndrome or Leber hereditary optic neuropathy. Mitochondrion, 2021, 60, 12-20.	1.6	4
124	Memory, processing of emotional stimuli, and volume of limbic structures in pediatric-onset multiple sclerosis. NeuroImage: Clinical, 2021, 31, 102753.	1.4	4
125	The health-related quality of life of children with multiple sclerosis is mediated by the health-related quality of life of their parents. Multiple Sclerosis Journal, 2022, 28, 1299-1310.	1.4	4
126	Preventing Multiple Sclerosis: The Pediatric Perspective. Frontiers in Neurology, 2022, 13, 802380.	1.1	4

#	Article	IF	Citations
127	Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study. BMJ Neurology Open, 2022, 4, e000215.	0.7	4
128	Autoantibodies against aquaporin-4 and myelin oligodendrocyte glycoprotein in paediatric CNS demyelination: Recent developments and future directions. Multiple Sclerosis and Related Disorders, 2012, 1, 116-122.	0.9	3
129	Pediatric multiple sclerosis. Neurology, 2016, 87, 822-826.	1.5	3
130	Clinical implications of status epilepticus in children. The Lancet Child and Adolescent Health, 2018, 2, 81-83.	2.7	3
131	A framework for measurement and harmonization of pediatric multiple sclerosis etiologic research studies: The Pediatric MS Tool-Kit. Multiple Sclerosis Journal, 2019, 25, 1170-1177.	1.4	3
132	Teaching Neuro Images : Intracranial vertebral dissection in a 15-year-old boy with sickle cell disease. Neurology, 2016, 87, e290-e291.	1.5	2
133	Imaging Pediatric Multiple Sclerosisâ€"Challenges and Recent Advances. Neuropediatrics, 2018, 49, 165-172.	0.3	2
134	Enhanced Recruitment During Executive Control Processing in Cognitively Preserved Patients With Pediatric-Onset MS. Journal of the International Neuropsychological Society, 2019, 25, 432-442.	1.2	2
135	Are children with multiple sclerosis really â€œoldâ€•adults. Multiple Sclerosis Journal, 2019, 25, 888-890.	1.4	2
136	Video Ambulatory EEG in Children: A Quality Improvement Study. Journal of Clinical Neurophysiology, 2022, 39, 271-275.	0.9	2
137	Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases. Multiple Sclerosis Journal, 2022, 28, 1819-1824.	1.4	2
138	Progressive retinal changes in pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 61, 103761.	0.9	2
139	Clinicopathologic conference: Loss of milestones and failure to thrive in a 28-month-old boy. Journal of Pediatrics, 2002, 140, 759-765.	0.9	1
140	Multiple sclerosis in children. Multiple Sclerosis and Related Disorders, 2012, 1, 3-5.	0.9	1
141	Paediatric neurology in 2016: a year in review. Lancet Neurology, The, 2017, 16, 14-15.	4.9	1
142	Complex genomic rearrangement in SPG11 due to a DNA replicationâ€based mechanism. Movement Disorders, 2017, 32, 1792-1794.	2.2	1
143	Neuroimaging in Pediatric Autoimmune Diseases. Journal of Pediatric Neurology, 2018, 16, 171-184.	0.0	1
144	Computerized Symbol Digit Modalities Test in a Swiss Pediatric Cohort Part 1: Validation. Frontiers in Psychology, 2021, 12, 631536.	1.1	1

#	Article	IF	Citations
145	Do prenatal sex hormones modulate MS risk?. Neurology, 2015, 85, 1193-1194.	1.5	0
146	Clinical trials for pediatric MS should be prioritized to test only one or two of the most promising agents â€“ YES. Multiple Sclerosis Journal, 2016, 22, 1649-1651.	1.4	0
147	Brain MRI and motor function in leukodystrophies. Neurology, 2016, 87, 748-749.	1.5	0
148	Diagnostic Challenges in Pediatric Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Journal of Pediatric Neurology, 2018, 16, 185-191.	0.0	0
149	Autoimmune Diseases of the Central Nervous System in Childhood. Journal of Pediatric Neurology, 2018, 16, 139-140.	0.0	0
150	Physical Activity and Sedentary Behavior Patterns Across Weekdays and Weekend Days in Youth With Multiple Sclerosis and Controls. International Journal of MS Care, 2022, 24, 8-12.	0.4	0
151	Serum 25â€hydroxyvitamin D as a determinant of multiple sclerosis outcome following a pediatric demyelinating event. FASEB Journal, 2009, 23, 345.8.	0.2	0
152	Disrupted cognitive development following pediatric acquired demyelinating syndromes: a longitudinal study. Child Neuropsychology, 2021, , 1-22.	0.8	0
153	Patterns of white and gray structural abnormality associated with paediatric demyelinating disorders. NeuroImage: Clinical, 2022, 34, 103001.	1.4	0
154	Researching COVID-19 in progressive MS requires a globally coordinated, multi-disciplinary and multi-stakeholder approachâ€”perspectives from the International Progressive MS Alliance. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732210991.	0.5	0